Adaptimmune Therapeutics PLC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q3 2024.
  • Adaptimmune Therapeutics PLC Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$17.6M, a 61.4% increase year-over-year.
  • Adaptimmune Therapeutics PLC Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$44.5M, a 53.2% increase year-over-year.
  • Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2023 was -$114M, a 31.2% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2022 was -$165M, a 4.66% decline from 2021.
  • Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2021 was -$158M, a 21.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$44.5M -$17.6M +$28M +61.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$72.5M $69.5M +$90.9M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$163M -$48.5M -$49.5M -4782% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$114M -$47.9M -$18.7M -63.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$95.2M -$45.6M -$4.18M -10.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$91M -$21.4M +$23.1M +52% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$114M $1.04M +$51.3M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$165M -$29.3M +$9.61M +24.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$175M -$41.4M +$980K +2.31% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$176M -$44.5M -$5.45M -14% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$171M -$50.3M -$12.5M -33.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$158M -$38.9M -$2.25M -6.13% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$156M -$42.4M -$6.97M -19.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$149M -$39.1M -$9.19M -30.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$140M -$37.8M -$9.6M -34.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$130M -$36.6M -$7.25M -24.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 -$123M -$35.4M +$3.87M +9.85% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$127M -$29.9M +$11.2M +27.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$138M -$28.2M -$755K -2.75% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$137M -$29.4M +$6.81M +18.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 -$144M -$39.3M -$44.5M -850% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$99.4M -$41.1M +$2.76M +6.29% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$102M -$27.4M -$6.67M -32.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$95.5M -$36.2M -$8.91M -32.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$86.6M $5.24M +$6.12M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$92.7M -$43.8M -$23.6M -117% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-06
Q1 2018 -$69.1M -$20.7M +$1.04M +4.79% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-06
Q4 2017 -$70.1M -$27.3M -$11.8M -76.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$58.3M -$878K +$17.6M +95.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$75.9M -$20.2M +$1.88M +8.51% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$77.8M -$21.8M -$6.21M -39.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$71.6M -$15.4M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$18.5M -$12.3M -196% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 -$22.1M -$7.53M -51.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 -$15.6M -$13.6M -701% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 -$6.24M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$14.6M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$1.95M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.